Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purposes of this study in United Network for Organ Sharing (UNOS) Status 1B (or country
equivalent) cardiac transplant candidates are to assess the safety and efficacy of Natrecor
(nesiritide). The study will evaluate the drug's ability to prevent clinical worsening when
administered as a 28-day continuous intravenous infusion in patients receiving standard care
and continuous intravenous infusion of dobutamine or milrinone.